Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Raw Materials: 2023-2025

Historic Raw Materials for Tonix Pharmaceuticals Holding (TNXP) over the last 1 years, with Sep 2025 value amounting to $2.5 million.

  • Tonix Pharmaceuticals Holding's Raw Materials fell 25.82% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 25.82%. This contributed to the annual value of $3.1 million for FY2024, which is 14.95% down from last year.
  • Tonix Pharmaceuticals Holding's Raw Materials amounted to $2.5 million in Q3 2025, which was up 5.84% from $2.3 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Raw Materials' 5-year high stood at $3.6 million during Q4 2023, with a 5-year trough of $2.3 million in Q2 2025.
  • Moreover, its 3-year median value for Raw Materials was $2.9 million (2024), whereas its average is $2.9 million.
  • Data for Tonix Pharmaceuticals Holding's Raw Materials shows a maximum YoY fell of 25.82% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's Raw Materials stood at $3.6 million in 2023, then declined by 14.95% to $3.1 million in 2024, then declined by 25.82% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $2.3 million for Q2 2025, and $2.7 million during Q1 2025.